Actionable trade ideas with defined risk and time horizons.
Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.
10,935 total articles
Berkshire Hathaway is trading below its 50-day and 20-day averages on weak momentum, but the underlying fundamentals remain robust: $1.04T market cap, P/E ~15.4, free cash flow of $19.3B and a low debt load. This trade targets a reversion to the 52-week high while keeping risk tight below recent lows.
Carlisle Companies (CSL) is a high-quality operator in roofing, insulation and waterproofing that combines durable free cash flow, a disciplined capital return program, and structural demand drivers (energy codes, severe-weather resilience) to offer a defensively biased growth trade. Valuation is reasonable relative to cash generation: market cap ~…
Supernus is a mid-cap CNS specialist with a stabilizing cash flow profile, an active pipeline (SPN-817) and a strategic acquisition of Sage Therapeutics. The balance sheet and free cash flow generation support valuation upside from current levels. We recommend a buy with specific entry, stop and target for a 180-trading-day horizon.
Envela (ELA) is a small-cap recycler and re-commerce operator whose exposure to secondary-market bullion and reclaimed precious metals gives it direct leverage to rising gold. The stock trades near $13.64 after a pullback; with a market cap around $353M, modest leverage, positive free cash flow and a tight float, a renewed gold rally and improving …
BioMarin (BMRN) offers a measurable risk-reward as a mid-term swing trade. Entry at the current price captures near-term upside from Amicus integration, steady free cash flow, and a valuation that still looks reasonable versus growth prospects. We lay out an actionable plan with a $72 target and a $51.50 stop over a 45-trading-day horizon.
Duolingo is down sharply from its 2025 highs but still generates strong free cash flow, has low leverage and high returns on capital. Technicals show oversold conditions and elevated short interest that can fuel a squeeze. This trade idea outlines an actionable entry at $134.08, a $210 target over the next 180 trading days, and a $110 stop — with c…
Dassault Systèmes (DASTY) offers a compelling long trade: attractive exposure to industrial digitalization and emerging markets like materials informatics and in‑silico trials, a reasonable valuation at a $36.9B market cap and upside to $38 if execution and adoption accelerate. Set a disciplined stop at $24.50 and plan for a long term (180 trading …
Evolution AB (EVVTY) is trading near its 52-week low despite a strong franchise in live casino solutions, a healthy dividend yield and a P/E of ~10.7. Technicals show downside pressure but also oversold momentum. This trade idea argues for a long position sized as risk-tolerant exposure: entry $65.00, target $85.00, stop $60.00, long-term horizon (…
Western Union (WU) trades at bargain multiples — roughly 5x earnings and ~5x EV/EBITDA — while yielding north of 10%. Immigration policy risk and fintech competition create tangible downside, but the stock's valuation, recurring free cash flow, and catalysts (Solana stablecoin, digital services growth, possible buybacks) make a mid-term long trade …
Apple reported a blowout fiscal Q1 with $143.8B revenue and $85.3B in iPhone sales. With peers repriced on AI froth and memory-price uncertainty, Apple looks like a lower-beta way to capture tech upside. We upgrade to a buy and lay out an actionable mid-term trade: entry $259.49, stop $248.00, target $288.00 (45 trading days).
A heavy Jan selloff has pushed AppLovin (APP) into oversold territory despite 68% revenue growth and $3.35B in free cash flow. Headlines about Alphabet's Project Genie are acting as a convenient scapegoat for the software rout; the fundamentals and cash generation argue for a mid-term long trade with defined risk controls.
Brown-Forman (BF.B) has been punished by cyclical demand and regional headwinds, but the business remains cash generative, carries manageable leverage, and trades at reasonable multiples. This trade idea outlines a long-term buy with specific entry, stop, and target levels and frames the risks and catalysts that will determine whether this setup pa…
Regeneron looks attractively valued for a 2026 re-acceleration. After a mixed quarter where Eylea faced pressure but company-level revenues and cash flow held up, the stock trades at ~17-18x forward earnings with strong free cash flow. Upcoming pipeline readouts, label expansions, and a material manufacturing buildout create a plausible path to dou…
Starbucks is showing early signs of a meaningful operational reset: comparable-store sales accelerated to +4% and U.S. transactions turned positive for the first time in eight quarters. Valuation is rich by historical earnings multiples, but the company still generates meaningful free cash flow and yields 2.66% in dividends. This trade targets a mi…
S&P Global is positioned to capture outsized value as it standardizes private-market data and completes the Mobility spin-off in 2026. The company generates strong free cash flow, maintains a conservative balance sheet, and just raised the dividend modestly while preparing to separate Mobility. That combination argues for a re-rating over the next …
Amerant (AMTB) offers a risk/reward that looks attractive if CRE stress continues to stabilize. The franchise trades at roughly $21.72 with a market cap under $1.0B, P/E ~13x and P/B below 1.0. We propose a long trade sized for a mid-to-long holding period, with a clear entry, stop and target tied to a re-rating and improving fundamentals.
iRhythm's recent selloff over a delayed product launch created a buying opportunity. With 2026 guidance of $870-880M (17-18% growth), positive free cash flow, $1.74B of cash on the balance sheet and an EV/sales multiple in the mid-single digits, the risk/reward favors a long trade sized for a volatility-aware portfolio. This idea lays out an entry,…
ProKidney's autologous renal cell therapy, rilparencel, showed statistically significant Phase 2 improvements in eGFR slope and an encouraging safety profile. With a market capitalization near $280M, an EV of roughly $185M and active short interest, the stock offers an asymmetric risk/reward to disciplined traders. This trade idea lays out an entry…
Benitec Biopharma’s BB-301 program just cleared two practical hurdles: convincing early efficacy/durability in Oculopharyngeal Muscular Dystrophy (OPMD) and a $100 million financing that materially derisks development funding. Given the clinical readouts (including 24-month durability in patient 1) and an EV of roughly $318M, a long trade with defi…
Kirby (KEX) trades at a mid-teens to low-twenties multiple on current earnings and offers solid free cash flow and an active buyback program. That makes the valuation interesting for a tactical long, but recent weakness in momentum indicators and lingering macro risks argue for a disciplined entry, a clear stop, and a mid-term horizon to let fundam…
EOPSF is an OTC-traded, small-cap defense optics play exposed to accelerating counter-drone demand. Technicals show the stock sitting above its 50-day average but below short-term momentum averages, while aggressive shorting and episodic volume create the potential for a rapid move. This trade idea lays out a mid-term (45 trading days) swing entry,…
Bonterra Energy (BNEFF) has shown follow-through above its short- and medium-term moving averages and carries meaningful short interest. Combine bullish technicals (RSI ~65, MACD bullish), recent strong Charlie Lake results, and a crowded short base for a mid-term long swing. Entry at $3.65, stop at $3.05, target $4.50 for a mid-term (45 trading da…
GPMT trades at a deeply depressed price-to-book (~0.17) with a market cap near $101M and heavy leverage embedded in enterprise value. Fundamentals and technicals suggest the downside that drove the discount is largely priced in. A focused long with a clear entry, stop and target offers asymmetric upside if the market re-rates the stock back toward …
Aon delivered results and balance-sheet actions that reinforce its role as a cash-generative, high-return insurance broker. With free cash flow at $3.04B, ROE north of 34%, and $2.2B net proceeds from the NFP wealth sale, the company is in a position to continue buybacks and dividend growth. Valuation is not cheap but looks reasonable against durab…
Brookdale has moved from restructuring to execution: occupancy is rising, cash burn is falling and the stock is carving out a higher base. The valuation already reflects leverage to operations rather than real estate recovery, making a disciplined long with a clear stop and target a practical trade for traders seeking a mid-term rebound.
